Trials / Completed
CompletedNCT00799825
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 346 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 580299/008 and received the control vaccine (Hepatitis A vaccine).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GSK Biological's HPV vaccine GSK580299 (Cervarix™) | All subjects will receive a 0.5 ml dose administered as an intramuscular injection, according to a 0, 1, 6-month schedule. |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2012-08-02
- Completion
- 2012-08-02
- First posted
- 2008-12-01
- Last updated
- 2018-07-12
- Results posted
- 2013-09-20
Locations
48 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00799825. Inclusion in this directory is not an endorsement.